Clinical Practice Guidelines Primary biliary cholangitis



About these slides

- These slides give a comprehensive overview of the EASL clinical practice guidelines on the management of primary biliary cholangitis
- The guidelines were published in full in the July 2017 issue of the Journal of Hepatology
 - The full publication can be downloaded from the <u>Clinical Practice</u> <u>Guidelines</u> section of the EASL website
 - Please cite the published article as: EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol 2017;67:145–72
- Please feel free to use, adapt, and share these slides for your own personal use; however, please acknowledge EASL as the source



About these slides

- Definitions of all abbreviations shown in these slides are provided within the slide notes
- When you see a home symbol like this one: , you can click on this to return to the outline or topics pages, depending on which section you are in

These slides are intended for use as an educational resource and should not be used in isolation to make patient management decisions. All information included should be verified before treating patients or using any therapies described in these materials

Please send any feedback to: <u>slidedeck_feedback@easloffice.eu</u>



Guideline panel

Chair

- Gideon M Hirschfield

Panel members


 Ulrich Beuers, Christophe Corpechot, Pietro Invernizzi, David Jones, Marco Marzioni, Christoph Schramm

Reviewers

 Kirsten M Boberg, Annarosa Floreani, Raoul Poupon









Methods

Grading evidence and recommendations

Grading evidence and recommendations

Grading is adapted from the GRADE system¹

Grade of evidence				
1	Randomized, controlled trials			
II-1	Controlled trials without randomization			
II-2	Cohort or case-control analytical studies			
II-3	Multiple time series, dramatic uncontrolled experiments			
Ш	Opinions of respected authorities, descriptive epidemiology			
Grade	Grade of recommendation			
1	Strong recommendation: Factors influencing the strength of the recommendation included the quality of the evidence, presumed patient-important outcomes, and cost			
2	Weaker recommendation: Variability in preferences and values, or more uncertainty; more likely a weak recommendation is warranted Recommendation is made with less certainty: higher cost or resource consumption			



Background

Epidemiology of PBC PBC pathogenesis

Epidemiology of PBC

- Remains a female predominant disease
 - Mainly >40 years
 - Does not present in childhood
- **Global:** Estimated 1 in 1,000 women over the age of 40 years old living with PBC
- **Europe:** Estimated incidence 1–2 per 100,000 population per year
 - Incidence range: 0.3–5.8 per 100,000
 - Prevalence range: 1.9-40.2 per 100,000



Pathogenesis of PBC

- Effective biliary secretion is essential for adequate hepatic detoxification and is integral to digestive function
- PBC reflects the consequences of immune and cellular injury to biliary epithelial cells, resulting in cholestasis and progressive liver fibrosis



EASL CPG PBC. J Hepatol 2017;67:145-72

Impact of PBC

- Patients can progress to end-stage liver disease
 - Average survival (historical) among those untreated is 9–10 years
- Symptoms associated with PBC impact on QoL, and include:
 - Pruritus
 - Sicca complex
 - Abdominal discomfort
 - Jaundice
 - Fatigue
 - Restless legs
 - Insomnia
 - Depression
 - Cognitive dysfunction

Life-long care that is structured and individualized is required

Goal is to prevent end-stage complications of liver disease and manage associated symptoms* that reduce QoL





Guidelines

Key recommendations

Topics

- 1. Diagnostic approach to cholestasis
- 2. Initial diagnosis of PBC
- 3. Stratification of risk in PBC
- 4. Defining inadequate response to treatment
- 5. Prognostic tools for PBC in practice: guidance
- 6. Treatment: therapies to slow disease progression
- 7. Special settings: pregnancy
- 8. PBC with features of autoimmune hepatitis
- 9. Management of symptoms
- 10. Management of complications of liver disease
- 11. Organisation of clinical care delivery

Click on a topic to skip to that section






Diagnostic approach to cholestasis

• A systematic approach to diagnosis of PBC is recommended

Recommendations* Grade of evidence	ade of recom	mendation
Take detailed history and physical examination when evaluating patients with biochemical tests that suggest cholestatic liver disease	Ш	1
Ultrasound should be the first-line non-invasive imaging procedure to differentiate intra- from extrahepatic cholestasis	Ш	1
Perform serological screening for AMA and PBC-specific ANA by immunofluorescence in all patients with unexplained cholestasis	Ш	1
Image using MRCP in patients with unexplained cholestasis. EUS can be an alternative to MRCP to evaluate distal biliary disease	III	1
Consider liver biopsy after serological screening and extended imaging in patients with ongoing unexplained intrahepatic cholestasis	Ш	1
Consider genetic tests for inherited cholestatic syndromes in patients where clinically appropriate	Ш	1







*Lasting for >6 months EASL CPG PBC. J Hepatol 2017;67:145–72

Initial diagnosis of PBC

- PBC should be suspected in patients with persistent cholestatic serum liver tests or symptoms
 - Including pruritus and fatigue

Recommendations* Grade of evidence	Grade of recom	mendation
In adults with cholestasis and no likelihood of systemic disease, elevated ALP plus AMA at a titre >1:40 is diagnostic	an III	1
In the correct context, a diagnosis of AMA-negative PBC can be made in patients with cholestasis and specific ANA immunofluorescence (nuclear dots or perinuclear rims) or ELIS results (sp100, gp210)	SA III	1
Liver biopsy not required for diagnosis of PBC, unless PBC-sp antibodies absent, coexistent AIH or NASH suspected, or other (usually systemic) comorbidities are present	ecific III	1
AMA reactivity alone is not sufficient to diagnose PBC . Follo patients with normal serum liver tests who are AMA positive with annual biochemical reassessment for the presence of liver disea	. III	1



Overview of utility of investigations in PBC

• Elevated ALP is typical of PBC

Test	Finding	Suspicion	Diagnosis	Prognosis
ALP		~	 ✓ 	 Image: A start of the start of
AST/ALT		v		 Image: A start of the start of
GGT		v		
lgM		v		
AMA (>1/40)	+		 ✓ 	
Specific ANA	+		 ✓ 	
Anti-gp210	+		 ✓ 	v
Anti-sp100	+		 ✓ 	
Anti-centromere	+			 ✓
Bilirubin				 ✓
Platelets				 ✓
INR				 ✓
Albumin				v




Overview of utility of investigations in PBC

• Elevated ALP is typical of PBC

Test	Finding	Notes
ALP		Values associated with disease progression
AST/ALT		□ □ May be suggestive of PBC with features of AIH
GGT		Reflects cholestatic liver injury
lgM		Elevated values associated with disease
AMA (>1/40)	+	Diagnostic in >90% of cases in correct clinical context
Specific ANA	+	Specific immunofluorescence patterns* present in 30%
Anti-gp210	+	Specific immunoassays available
Anti-sp100	+	Specific immunoassays available
Anti-centromere	+	Associated with portal hypertensive phenotype
Bilirubin		Elevation at late stages frequently indicative of cirrhosis [†]
Platelets		Indicative of cirrhosis
INR		Indicative of cirrhosis
Albumin		Indicative of cirrhosis




- Liver biopsy is not generally required to diagnose PBC
 - Essential when:
 - PBC-specific antibodies are absent
 - Co-existent AIH or NASH is suspected
 - With other systemic/extrahepatic co-morbidities






- Liver biopsy is not generally required to diagnose PBC
 - Essential when:
 - PBC-specific antibodies are absent
 - Co-existent AIH or NASH is suspected
 - With other systemic/extrahepatic co-morbidities






*Haematoxylin and eosin stain EASL CPG PBC. J Hepatol 2017;67:145–72


- Liver biopsy is not generally required to diagnose PBC
 - Essential when:
 - PBC-specific antibodies are absent
 - Co-existent AIH or NASH is suspected
 - With other systemic/extrahepatic co-morbidities




Expanded portal tract contains arterial branches without accompanying bile ducts Marginal ductular reaction associated with loose fibrosis (biliary interface activity)* Absence of properly formed bile ducts/presence of prominent marginal ductular reaction[†]




- Liver biopsy is not generally required to diagnose PBC
 - Essential when:
 - PBC-specific antibodies are absent
 - Co-existent AIH or NASH is suspected
 - With other systemic/extrahepatic co-morbidities



In the presence of prominent interface hepatitis associated with ballooning, rosetting and entrapment of periportal hepatocytes, additional autoimmune hepatitis should be considered. Focal lymphocyte emperipolesis is also present*



- Liver biopsy is not generally required to diagnose PBC
 - Essential when:
 - PBC-specific antibodies are absent
 - Co-existent AIH or NASH is suspected
 - With other systemic/extrahepatic co-morbidities



Established cirrhosis with broad fibrous septa surrounding small hepatocyte nodules Septa have narrow peripheral 'halo zones' of loose fibrosis characteristic of chronic biliary disease*



*Haematoxylin Van Gieson EASL CPG PBC. J Hepatol 2017;67:145–72

Stratification of risk in PBC

- Even when treated, PBC can remain a progressive disease
 - Risk of liver-related complications
 - Risk of death
- All patients should be evaluated for their risk of developing progressive PBC*
 - Consequently, their potential need for additional treatments

High- and low-risk disease defined by:

• Evaluation of response to first-line agent UDCA

Greatest **risk of disease complications** identified by:


- Age at onset
- Sex (male)
- Stage at presentation
- Selected biochemical/ serological indices pre- and post-therapy with UDCA



Recommendations*	rade of	
Recognize that patients at greatest risk of complications from PBC have inadequate biochemical response to therapy , and cirrhosis	II-2	1
Actively recognize that the strongest risk factors for inadequate biochemical response to therapy are early age at diagnosis (e.g. <45), and advanced stage at presentation	III	1
Evaluate all patients for stage of disease using a combination of non-invasive tests (bilirubin, alkaline phosphatase, AST, albumin, platelet count and elastography) at baseline, and during follow-up	III	1
 Elevated serum bilirubin and ALP can be used as surrogate markers of outcome for patients with PBC Routine biochemistry and haematology indices should underpin clinical approaches to stratify individual risk of disease progression 	II-2	1
Recognize that transplant-free survival for early-stage patients with ALP <1.5x ULN and a normal bilirubin after 1 year of therapy with UDCA, is not significantly different to a control healthy population	II-2	1
Use elastography and risk scores (eg, GLOBE and UK-PBC score) for patients with PBC, to help better define individual risk of developing complications of advanced liver disease in the future	III	1



Three pillars of PBC management



Defining inadequate response to treatment

- Treatment failure must be defined on validated surrogate endpoints
 - To account for the slow progression of disease
- Qualitative biochemical response to UDCA assessed using binary definitions or continuous scoring

Binary definitions	Time (months)	Treatment failure	
Rochester ¹	6	ALP ≥2 ULN or Mayo score ≥4.5	
Barcelona ²	12	Decrease in ALP ≤40% and ALP ≥1x ULN	
Paris-I ³	12	ALP ≥3x ULN or AST ≥2x ULN or bilirubin >1 mg/dl	
Rotterdam ⁴	12	Bilirubin ≥1x ULN and/or albumin <1x ULN	
Toronto ⁵	24	ALP >1.67x ULN	
Paris-II ⁶	12	ALP ≥1.5x ULN or AST ≥1.5x ULN or bilirubin >1 mg/dl	
Ehime ⁷	6	Decrease in GGT ≤70% and GGT ≥1 ULN	
Continuous scoring	Time (months)	s) Scoring parameters	
UK-PBC ⁸	12	12 months: bilirubin, ALP and AST (or ALT); Baseline: albumin and platelets	
GLOBE ⁹	12	12 months: bilirubin, ALP, albumin, and platelet count; Baseline: age	



Prognostic tools for PBC in practice: guidance

- Prognostic tools allow:
 - Selection of patients for second-line therapies
 - Risk stratification in clinical trials to account for prognostic disparity

Rational approaches to risk stratification in PBC				
Level of applicability	Prognostic tools			
High (High applicability, robust validation)	 On-treatment ALP and bilirubin-based assessment of response to UDCA Baseline disease stage* as defined by elastography, serum levels of bilirubin and albumin, or histology 			
Moderate (High applicability, further validation pending)	 LSM by elastography APRI ELF test 			
Indeterminate (Limited applicability and/or validation)	 Age, gender and symptom profile PBC-specific ANA Degree of interface hepatitis and ductopenia Novel histological scoring systems Direct measurement of portal pressure 			



*Early vs. advanced (histology on biopsy, absent or mild vs. bridging fibrosis or cirrhosis; Elastography, LSM ≤9.6 kPa vs. >9.6 kPa; Serum bilirubin and albumin, both normal vs. ≥1 elevated) EASL CPG PBC. J Hepatol 2017;67:145–72

Treatment: therapies to slow disease progression



- Ursodeoxycholic acid (UDCA) and obeticholic acid (OCA) approved in PBC
- Heterogeneity of treatment efficacy in clinical trials may be due to:
 - Variable inclusion criteria without reference to disease risk or stage

Recommendations* Grade of evidence Grade	de of recomr	nendation
Oral UDCA: 13–15 mg/kg/day as the first-line pharmacotherapy for all patients with PBC. UDCA is usually continued for life	I	1
 Oral OCA: Biochemical efficacy in patients with ALP >1.67x ULN and/or bilirubin elevated <2x ULN demonstrated in a Phase 3 study Conditionally approved for patients with PBC in combination with UDCA for those with an inadequate response to UDCA, or as monotherapy in those intolerant to UDCA Consider use in such patients (initial dose 5 mg; dose titration to 10 mg according to tolerability at 6 months) 	I	2
Data from Phase 3 randomized trials for budesonide (in non-cirrhotic patients), and bezafibrate , both in combination with UDCA , not yet published; currently, a recommendation for therapy cannot be made	II-2	2



Special settings: pregnancy

- A minority of women diagnosed with PBC are of reproductive age
- UDCA is safe during conception, pregnancy and post-partum according to expert clinical opinion

Recommendations* Grade of evidence	ade of recom	mendation
 Expert consultation is required for all pregnant patients to guide therapy. Pregnancy is typically well tolerated in non-cirrhotic patients with PBC Continue UDCA in pregnancy, even though data are limited Pruritus management is important and may require specialist advice; rifampicin has been used by experts during third trimester 	III	1
 Pregnancy in patients with cirrhosis carries a higher risk of maternal and foetal complications Offer pre-conception counselling and relevant specialist monitoring 	III	1



PBC with features of autoimmune hepatitis

- ~8–10% of patients with PBC have features characteristic of AIH
 - 'AIH-PBC overlap syndrome', 'hepatitic form of PBC', or 'PBC with secondary AIH'
- With non-response to UDCA after 6–12 months additional AIH features should be investigated
 - Paris criteria used most commonly[†]

Recommendations* Grade of evidence Grade	ide of recomr	nendation
Liver biopsy is mandatory in confirming the features of AIH, and should be considered in patients with disproportionate elevations in ALT and/or IgG	III	1
 Patients with PBC and typical features of AIH may benefit from immunosuppressive treatment in addition to UDCA Use immunosuppressive treatment in patients with severe interface hepatitis, and consider in patients with moderate interface hepatitis Counsel patients about immunosuppressive treatment side effects 	III	2

*Statements 24, 25; [†]According to these criteria, a diagnosis can be made in a patient with PBC with at least two of the following: 1. ALP >2x ULN or GGT >5x ULN. 2. AMA >1:40. 3. Florid bile duct lesion on histology **AND** two of the following three features: 1. ALT >5x ULN. 2. IgG serum levels >2x ULN or smooth muscle autoantibody positive. 3. Moderate or severe interface hepatitis on histology EASL CPG PBC. J Hepatol 2017;67:145–72



Management of symptoms

- Symptoms associated with PBC have a significant impact on QoL

Recommendations* Grade of evidence	ade of recom	mendation
Screening: Evaluate all patients for presence of symptoms, particularly pruritus, sicca complex and fatigue. Severity of symptoms not necessarily correlated with stage of disease in PBC	Ш	1
Pruritus		
 Treat using a step-wise approach. Severe pruritus may indicate an aggressively ductopenic variant of PBC. These patients have a poor prognosis and should be referred to an expert centre 	Ш	1
 First-line: cholestyramine as first-line therapy. Avoid interaction with other medications 	II-2	1
 Second-line: rifampicin[†] 	II-2	1
Fatigue		4
Seek and treat associated and alternate causes of fatigue	111	1
Advise patients with fatigue on developing coping strategies	III	2
Sicca complex: where appropriate consider expert referral		1
Miscellaneous: Refer patients with symptoms resistant to medical therapy for specialist management, regardless of disease severity		1





• Osteoporosis is a common complication in PBC

Recommendations* Grade of evidence Grade of recommendation		
Consider the risk of osteoporosis in all patients with PBC	III	1
To assess risk, consider use of DEXA to assess bone mineral density at presentation and at follow-up where Indicated	Ш	1
Supplement patients with PBC with calcium and vitamin D , according to local practice	Ш	2
Bisphosphonates are safe and effective treatments for patients with PBC and significantly elevated fracture risk from osteoporosis. Use with caution in patients with varices. Initiate therapy according to specific osteoporosis guidelines	II-2	1



• Fat soluble vitamin malabsorption can occur in PBC

Recommendations*	Grade of evidence 📕 Gra	ade of recom	mendation
Fat-soluble vitamin malabsorption: Can with prolonged jaundice. Supplementation sindividual basis	· 1 _ 3	III	2

- Serum lipids can be elevated in up to 80% of patients with PBC
 - Underlying mechanism is different to that of other conditions
 - No substantial evidence to support an elevated CV risk

Recommendations [†]	Grade of evidence 📕 Gra	ade of recom	mendation
Hyperlipidaemia: In patients with PBC and cholesterol, low HDL-C cholesterol, high LE cholesterol-lowering agents on a case-by-c contraindicated)L-C, consider	III	2



- Patients with PBC may develop portal hypertension as a result of biliary cirrhosis
 - Associated with a poor prognosis

Recommendations*	Grade of evidence	ade of recom	mendation
Varices: Baveno-VI guidelines for screening varices apply equally to patients with PBC	5	ш	2

- HCC is one of the most serious complications of PBC
 - Incidence of HCC in those with diagnosed PBC is 0.36 per 100 person years

Recommendations [†]	Grade of evidence 📕 Gra	ide of recom	mendation
Hepatocellular carcinoma: In patients w surveillance according to EASL guidelines	• •	Ш	2



- PBC as an indication for liver transplant is declining
 - Despite increasing prevalence of PBC
- Outcome post-liver transplant is usually favourable and better for most other liver transplant indications
 - 5-year survival of 80-85%

Recommendations*	rade of recom	mendation
Liver transplantation		
 Consider patients for transplant assessment when presenting with complications of cirrhosis, markers of disease severity (e.g. persistent elevated bilirubin values [50 µmol/l or 3 mg/dl] or MELD >15), or severe medically resistant pruritus. Follow local (usually national) guidelines 	II-2	1
In patients with proven or likely recurrent PBC post-liver transplan use of UDCA is safe and can improve liver biochemistry	' II-2	2



Organisation of clinical care delivery

- Advent of stratified therapy has increased the complexity of managing patients with PBC
- Optimal care models must be flexible
 - Effectively manage high-risk patients/those with a high symptom burden
 - Avoid over-management of low-risk asymptomatic patients

Recommendations* Grade of evidence Grade	ade of recomr	nendation
Care pathways:		
All patients with PBC should have structured life-long follow-up	Ш	1
Develop care pathway for PBC based on these guidelines	III	2
Clinical care standards: Use standardized clinical audit tools to document and improve the quality of care delivered to patients	Ш	2
Patient support: Inform patients of support available from patient support groups, including access to patient education material	Ш	2



Proposed clinical care standards for PBC

s receiving therapy at nted to be intolerant
s receiving UDCA to criteria used recorded
s have the presence/ complex and fatigue st year
ation that discussion onths of relevant clinical n recorded
ent within the last
s with diagnosis of PBC ver biopsy confirmation cussion noted

